Transaction · 0001104659-26-106308

Chan Phillip P.

Chan Phillip P., CEO, reported an open-market or private purchase at Cytosorbents Corp involving 200000.000000 shares for an estimated $70000.00. Reported holdings after the transaction were 1944432.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

Open-market buySEC transaction code PCEO
CTSOCytosorbents Corp
Trade date
Sep 04, 2026
Filing date
Sep 09, 2026
View on SEC Insider profile
Estimated value$70.0kShares × reported price
Shares traded200k$0.35 per share
Holdings after1.94MDirect
% of reported position traded11.47%This security and ownership context
How reported position traded is calculated

Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 1,744,432 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

CTSO price since this filing

Daily closing prices, with the filing date and available return windows
CTSO · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago1d ago
Returns since7d -9.5%30d -41.1%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Buy
Code P
Identifier
0001104659-26-106308
Common Stock
Transaction date
Sep 04, 2026
Filed Sep 09, 2026, 08:05 PM · 5d delay
Shares
200,000 sh
$0.35 per share
Estimated value
$70.0k
Computed from shares × price
Holdings after
1,944,432 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
CEO Buy Director Buy Direct Ownership
Filing-only score

+30 points

Compact filing score computed from stored Form 4 facts. Version v1.

Strong filing signal

This filing has a high positive filing-only score. It may deserve closer research, but it is not an investment recommendation.

How this score is calculated
  • open_market_purchase+12 points

    transaction_code = P

    Code P is a discretionary open-market purchase.
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • ceo_buy+12 points

    is_officer + officer_title/role mentions CEO

    CEO open-market purchase.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Executive Officer

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    The transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person. The price reported in Column 4 is a weighted average

  2. price. These shares were purchased in multiple transactions at prices ranging from $0.3470 to $0.3599, inclusive. The Reporting Person undertakes to provide to

  3. CytoSorbents Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full

  4. information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

  5. F2

    Includes: (i) the following restricted stock units ("RSUs") that will be settled into shares of Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restat…

  6. F3

    (continued from footnote 2) (ii) 52,800 RSUs of 105,600 granted on August 8, 2025, which vest in equal parts at the first and second year anniversaries of the date of grant, subject to the Reporting P…

  7. F4

    The shares reported herein were not adjusted to reflect the Issuer's reverse stock split that occurred on September 8, 2026.

Original filing · 0001104659-26-106308
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

CTSO